The University of Chicago Header Logo

Connection

George Bakris to Risk Factors

Back to Details
This is a "connection" page, showing publications George Bakris has written about Risk Factors.
George Bakris
Connection Strength
5.188
Risk Factors
  1. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol. 2023 08 01; 8(8):732-741.
    View in: PubMed
    Score: 0.110
  2. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747.
    View in: PubMed
    Score: 0.110
  3. Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187.
    View in: PubMed
    Score: 0.097
  4. Intersection Between Chronic Kidney Disease and Cardiovascular Disease. Curr Cardiol Rep. 2021 07 16; 23(9):117.
    View in: PubMed
    Score: 0.096
  5. Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. Diabetes Obes Metab. 2021 07; 23(7):1580-1587.
    View in: PubMed
    Score: 0.094
  6. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714.
    View in: PubMed
    Score: 0.092
  7. Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance. Hypertension. 2020 04; 75(4):943-944.
    View in: PubMed
    Score: 0.087
  8. Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254.
    View in: PubMed
    Score: 0.087
  9. Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circ Res. 2019 03 29; 124(7):969-971.
    View in: PubMed
    Score: 0.082
  10. Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes Care. 2018 04; 41(4):662-663.
    View in: PubMed
    Score: 0.076
  11. MY APPROACH to the elderly patient with resistant hypertension. Trends Cardiovasc Med. 2018 01; 28(1):79-80.
    View in: PubMed
    Score: 0.074
  12. Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846.
    View in: PubMed
    Score: 0.073
  13. The Kidney in Hypertension. Med Clin North Am. 2017 Jan; 101(1):207-217.
    View in: PubMed
    Score: 0.070
  14. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015 Oct 17; 386(10003):1588-98.
    View in: PubMed
    Score: 0.064
  15. Update on blood pressure goals in diabetes mellitus. Curr Cardiol Rep. 2015 Jun; 17(6):37.
    View in: PubMed
    Score: 0.063
  16. Cardiovascular disease in CKD in 2014: new insights into cardiovascular risk factors and outcomes. Nat Rev Nephrol. 2015 Feb; 11(2):70-2.
    View in: PubMed
    Score: 0.061
  17. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75.
    View in: PubMed
    Score: 0.057
  18. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. Am J Med. 2014 Jan; 127(1):S1.
    View in: PubMed
    Score: 0.056
  19. Interventional cardiology: Indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013 Aug; 10(8):434-6.
    View in: PubMed
    Score: 0.055
  20. Recognition and management of masked hypertension: a review and novel approach. J Am Soc Hypertens. 2013 May-Jun; 7(3):244-52.
    View in: PubMed
    Score: 0.054
  21. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013 Mar; 15(3):340.
    View in: PubMed
    Score: 0.054
  22. Clinical guidelines: blood pressure goals in T2DM: a Latin American perspective. Nat Rev Endocrinol. 2013 Mar; 9(3):138-9.
    View in: PubMed
    Score: 0.053
  23. Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. J Womens Health (Larchmt). 2012 Sep; 21(9):917-24.
    View in: PubMed
    Score: 0.050
  24. Hypertension in 2011: New insights--from risk factors to treatment implications. Nat Rev Cardiol. 2011 Dec 13; 9(2):75-7.
    View in: PubMed
    Score: 0.049
  25. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 May; 86(5):444-56.
    View in: PubMed
    Score: 0.047
  26. Renal function and target organ damage in hypertension. Eur Heart J. 2011 Jul; 32(13):1599-604.
    View in: PubMed
    Score: 0.047
  27. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2010 Nov; 28(4):545-59.
    View in: PubMed
    Score: 0.046
  28. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol. 2010 Sep; 8(5):604-11.
    View in: PubMed
    Score: 0.045
  29. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010 Oct; 78(8):726-36.
    View in: PubMed
    Score: 0.045
  30. Lower blood pressure goals in high-risk cardiovascular patients: are they defensible? Cardiol Clin. 2010 Aug; 28(3):447-52.
    View in: PubMed
    Score: 0.045
  31. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31(5):469-70.
    View in: PubMed
    Score: 0.044
  32. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary. Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S1-3.
    View in: PubMed
    Score: 0.044
  33. Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14.
    View in: PubMed
    Score: 0.044
  34. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81.
    View in: PubMed
    Score: 0.043
  35. Hypertension goals in advanced-stage kidney disease. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S92-4.
    View in: PubMed
    Score: 0.043
  36. The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep. 2009 Nov; 11(6):436-42.
    View in: PubMed
    Score: 0.043
  37. Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich). 2009 Nov; 11(11):636-43.
    View in: PubMed
    Score: 0.043
  38. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24.
    View in: PubMed
    Score: 0.042
  39. Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes Obes Metab. 2009 Aug; 11(8):757-69.
    View in: PubMed
    Score: 0.041
  40. Executive summary: Kidney Early Evaluation Program (KEEP) 2008 annual data report. Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S1-2.
    View in: PubMed
    Score: 0.041
  41. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S3-10.
    View in: PubMed
    Score: 0.041
  42. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Kidney Int. 2009 Mar; 75(5):449-52.
    View in: PubMed
    Score: 0.041
  43. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. Clin Nephrol. 2009 Mar; 71(3):239-43.
    View in: PubMed
    Score: 0.041
  44. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Blood Purif. 2009; 27(2):231-4.
    View in: PubMed
    Score: 0.041
  45. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Am J Nephrol. 2009; 30(1):95-8.
    View in: PubMed
    Score: 0.041
  46. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Clin J Am Soc Nephrol. 2009 Mar; 4(3):517-9.
    View in: PubMed
    Score: 0.040
  47. Hypertension and kidney disease: a combination that should be prevented. Nephrol News Issues. 2009 Feb; 23(2):42, 44, 46.
    View in: PubMed
    Score: 0.040
  48. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Pediatr Nephrol. 2009 Mar; 24(3):427-30.
    View in: PubMed
    Score: 0.040
  49. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Arch Iran Med. 2009 Jan; 12(1):102-5.
    View in: PubMed
    Score: 0.040
  50. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25; 52(22):1749-57.
    View in: PubMed
    Score: 0.040
  51. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens. 2008 Sep; 17(5):457-63.
    View in: PubMed
    Score: 0.039
  52. KEEP launches follow-up initiative aimed at predicting the future. Nephrol News Issues. 2008 Sep; 22(10):44-6.
    View in: PubMed
    Score: 0.039
  53. Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol. 2008 Oct; 97(10):713-25.
    View in: PubMed
    Score: 0.039
  54. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S30-7.
    View in: PubMed
    Score: 0.038
  55. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):130-9.
    View in: PubMed
    Score: 0.038
  56. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008 Jan; 3 Suppl 1:S3-10.
    View in: PubMed
    Score: 0.037
  57. Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors. J Cardiometab Syndr. 2008; 3(2):119-25.
    View in: PubMed
    Score: 0.037
  58. Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. Pol Arch Med Wewn. 2007 Sep; 117(9):389-90.
    View in: PubMed
    Score: 0.037
  59. Current perspectives on hypertension and metabolic syndrome. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S3-5.
    View in: PubMed
    Score: 0.036
  60. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. J Clin Hypertens (Greenwich). 2007 Mar; 9(3):196-200.
    View in: PubMed
    Score: 0.035
  61. The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? Am J Nephrol. 2007; 27(1):44-54.
    View in: PubMed
    Score: 0.035
  62. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol. 2006 Oct 02; 98(7A):46L-52L.
    View in: PubMed
    Score: 0.034
  63. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33.
    View in: PubMed
    Score: 0.034
  64. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant. 2006 Sep; 21(9):2366-74.
    View in: PubMed
    Score: 0.034
  65. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens. 2006 Sep; 20(9):693-700.
    View in: PubMed
    Score: 0.033
  66. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care. 2006 May; 29(5):1167-9.
    View in: PubMed
    Score: 0.033
  67. Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr. 2006; 1(1):58-65.
    View in: PubMed
    Score: 0.033
  68. Obesity and insulin resistance as risk factors for chronic kidney disease. J Cardiometab Syndr. 2006; 1(3):209-14; quiz 215-6.
    View in: PubMed
    Score: 0.033
  69. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension. 2005 Oct; 46(4):637-42.
    View in: PubMed
    Score: 0.032
  70. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
    View in: PubMed
    Score: 0.031
  71. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. Hypertension. 2004 May; 43(5):941-2.
    View in: PubMed
    Score: 0.029
  72. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004 Mar 08; 116 Suppl 5A:30S-38S.
    View in: PubMed
    Score: 0.029
  73. What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207.
    View in: PubMed
    Score: 0.028
  74. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003 Jul 14; 163(13):1555-65.
    View in: PubMed
    Score: 0.028
  75. Who should be treated with combination therapy as initial treatment for hypertension? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):21-8.
    View in: PubMed
    Score: 0.027
  76. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Postgrad Med. 2003 May; 113(5):35-40, 43-4, 50.
    View in: PubMed
    Score: 0.027
  77. Albuminuria and Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 01 24; 81(3):270-282.
    View in: PubMed
    Score: 0.027
  78. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023 02; 37(2):108389.
    View in: PubMed
    Score: 0.027
  79. Treatment of hypertension in patients with renal disease. Cardiovasc Drugs Ther. 2002 Dec; 16(6):503-10.
    View in: PubMed
    Score: 0.026
  80. Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. J Card Fail. 2023 01; 29(1):87-107.
    View in: PubMed
    Score: 0.026
  81. Hypertension and diabetes: family physicians' pivotal role. Am Fam Physician. 2002 Oct 01; 66(7):1151-2.
    View in: PubMed
    Score: 0.026
  82. Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. Postgrad Med. 2002 Oct; 112(4):73-4, 77-80, 83-4.
    View in: PubMed
    Score: 0.026
  83. External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial. Diabetes Obes Metab. 2023 01; 25(1):229-237.
    View in: PubMed
    Score: 0.026
  84. Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. Curr Diab Rep. 2002 Jun; 2(3):258-62.
    View in: PubMed
    Score: 0.025
  85. Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61.
    View in: PubMed
    Score: 0.025
  86. Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. J Diabetes Res. 2022; 2022:9998891.
    View in: PubMed
    Score: 0.025
  87. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2002 May; 20(2):195-206, v.
    View in: PubMed
    Score: 0.025
  88. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002 Feb; 7(1):35-43.
    View in: PubMed
    Score: 0.025
  89. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. Prog Brain Res. 2002; 139:289-98.
    View in: PubMed
    Score: 0.025
  90. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237.
    View in: PubMed
    Score: 0.024
  91. Choices and goals in the treatment of the diabetic hypertensive patient. Curr Hypertens Rep. 2001 Oct; 3(5):387-91.
    View in: PubMed
    Score: 0.024
  92. Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clin Res Cardiol. 2021 Oct; 110(10):1612-1624.
    View in: PubMed
    Score: 0.024
  93. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens (Greenwich). 2001 Mar-Apr; 3(2):99-102.
    View in: PubMed
    Score: 0.023
  94. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens. 2000 Oct-Nov; 14(10-11):667-85.
    View in: PubMed
    Score: 0.023
  95. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 06 09; 75(22):2836-2850.
    View in: PubMed
    Score: 0.022
  96. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000 Mar 30; 342(13):969-70.
    View in: PubMed
    Score: 0.022
  97. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar 13; 160(5):685-93.
    View in: PubMed
    Score: 0.022
  98. Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obes Metab. 2020 05; 22(5):798-806.
    View in: PubMed
    Score: 0.022
  99. Hypertension in patients with diabetes. Why is aggressive treatment essential? Postgrad Med. 2000 Feb; 107(2):53-6, 61-4.
    View in: PubMed
    Score: 0.022
  100. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452.
    View in: PubMed
    Score: 0.021
  101. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S.
    View in: PubMed
    Score: 0.021
  102. The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2019 03 01; 34(3):515-523.
    View in: PubMed
    Score: 0.020
  103. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550.
    View in: PubMed
    Score: 0.020
  104. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11).
    View in: PubMed
    Score: 0.019
  105. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
    View in: PubMed
    Score: 0.019
  106. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801.
    View in: PubMed
    Score: 0.018
  107. Renal mortality associated with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1997 Mar-Apr; 11(2):104-11.
    View in: PubMed
    Score: 0.018
  108. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671.
    View in: PubMed
    Score: 0.018
  109. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. Hypertension. 2017 02; 69(2):220-227.
    View in: PubMed
    Score: 0.017
  110. The Lanai Symposium: hypertensive patient profiles: approaches to management and disease prevention. J Hum Hypertens. 1997 Jan; 11(1):7-8.
    View in: PubMed
    Score: 0.017
  111. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255.
    View in: PubMed
    Score: 0.017
  112. Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis. 2016 Nov; 68(5S1):S51-S58.
    View in: PubMed
    Score: 0.017
  113. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med. 1996 Sep 30; 101(3A):33S-46S.
    View in: PubMed
    Score: 0.017
  114. BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol. 2017 02; 28(2):671-677.
    View in: PubMed
    Score: 0.017
  115. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
    View in: PubMed
    Score: 0.017
  116. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004.
    View in: PubMed
    Score: 0.017
  117. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9.
    View in: PubMed
    Score: 0.016
  118. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76.
    View in: PubMed
    Score: 0.015
  119. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995 Jan; 35(1):73-80.
    View in: PubMed
    Score: 0.015
  120. Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015 Jul; 278(1):38-49.
    View in: PubMed
    Score: 0.015
  121. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014 Dec; 20(12):953-8.
    View in: PubMed
    Score: 0.015
  122. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33.
    View in: PubMed
    Score: 0.015
  123. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43.
    View in: PubMed
    Score: 0.014
  124. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014 Feb; 32(2):415-22.
    View in: PubMed
    Score: 0.014
  125. Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients. J Hypertens. 2014 Feb; 32(2):423-31.
    View in: PubMed
    Score: 0.014
  126. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan; 7(1):51-8.
    View in: PubMed
    Score: 0.014
  127. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1135-44.
    View in: PubMed
    Score: 0.014
  128. Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly. Am J Nephrol. 2013; 38(3):195-203.
    View in: PubMed
    Score: 0.014
  129. Diabetic nephropathy. Dis Mon. 1993 Aug; 39(8):573-611.
    View in: PubMed
    Score: 0.014
  130. Diabetic nephropathy. What you need to know to preserve kidney function. Postgrad Med. 1993 Apr; 93(5):89-90, 93-5, 99-100.
    View in: PubMed
    Score: 0.013
  131. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 Jun; 126(6):501-8.
    View in: PubMed
    Score: 0.013
  132. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8.
    View in: PubMed
    Score: 0.013
  133. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov; 33(22):2782-95.
    View in: PubMed
    Score: 0.013
  134. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012 Feb; 163(2):156-63.
    View in: PubMed
    Score: 0.012
  135. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.012
  136. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
    View in: PubMed
    Score: 0.012
  137. Assessment and management of vascular disease risk in patients with chronic kidney disease. J Clin Lipidol. 2011 Jul-Aug; 5(4):251-60.
    View in: PubMed
    Score: 0.012
  138. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2010: executive summary. Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S1-3.
    View in: PubMed
    Score: 0.012
  139. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S24-31.
    View in: PubMed
    Score: 0.012
  140. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16.
    View in: PubMed
    Score: 0.012
  141. Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. Intern Med J. 2010 Dec; 40(12):833-41.
    View in: PubMed
    Score: 0.011
  142. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29; 56(1):77-85.
    View in: PubMed
    Score: 0.011
  143. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know? J Clin Hypertens (Greenwich). 2010 Jun; 12(6):422-30.
    View in: PubMed
    Score: 0.011
  144. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 05; 102(9):596-604.
    View in: PubMed
    Score: 0.011
  145. The editor's roundtable: prehypertension. Am J Cardiol. 2009 Oct 15; 104(8):1105-15.
    View in: PubMed
    Score: 0.011
  146. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
    View in: PubMed
    Score: 0.011
  147. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
    View in: PubMed
    Score: 0.010
  148. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14; 118(16):1643-50.
    View in: PubMed
    Score: 0.010
  149. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008 Aug; 156(2):277-83.
    View in: PubMed
    Score: 0.010
  150. A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure. Am J Cardiol. 2008 Jun 15; 101(12):1772-6.
    View in: PubMed
    Score: 0.010
  151. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S46-55.
    View in: PubMed
    Score: 0.010
  152. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation. 2008 Apr 01; 117(13):1685-92.
    View in: PubMed
    Score: 0.010
  153. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Feb; 51(2):192-8.
    View in: PubMed
    Score: 0.009
  154. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7.
    View in: PubMed
    Score: 0.009
  155. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007 Aug; 50(2):299-305.
    View in: PubMed
    Score: 0.009
  156. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007; 16(2):72-9.
    View in: PubMed
    Score: 0.009
  157. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 01; 99(3):393-8.
    View in: PubMed
    Score: 0.009
  158. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006 Oct 01; 98(7):890-4.
    View in: PubMed
    Score: 0.009
  159. The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management. Curr Pharm Des. 2006; 12(13):1567-79.
    View in: PubMed
    Score: 0.008
  160. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich). 2005 Feb; 7(2):73-80.
    View in: PubMed
    Score: 0.008
  161. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J. 2004 Aug; 148(2):243-51.
    View in: PubMed
    Score: 0.007
  162. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6):1206-52.
    View in: PubMed
    Score: 0.007
  163. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis. 2003 Jun; 41(6):1267-77.
    View in: PubMed
    Score: 0.007
  164. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21; 289(19):2560-72.
    View in: PubMed
    Score: 0.007
  165. Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained. Postgrad Med. 2002 Oct; 112(4):51-2, 55, 59-62 passim.
    View in: PubMed
    Score: 0.007
  166. Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med. 2002 Oct; 112(4):24-6, 29-30, 33-4 passim.
    View in: PubMed
    Score: 0.007
  167. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000 Feb 28; 160(4):481-90.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.